CureVac N.V. announced that after more than 10 years as a member of the CureVac management board and three years as CEO, Dr. Franz Haas will step down as CEO, effective March 31, 2023. Dr. Alexander Zehnder will succeed Dr. Haas, joining from Sanofi on April 1, 2023. Alexander is currently Global Head of Oncology at Sanofi and previously held country leadership positions at both headquarter and country level.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on CVAC:
- CureVac upgraded to Buy at Jefferies after mRNA platform validation
- CureVac (NASDAQ:CVAC) Rally Continues after Impressive Clinical Results
- CureVac upgraded to Buy from Hold at Jefferies
- CureVac ‘likely too late for COVID upside,’ says BofA
- CureVac announces data on joint COVID-19, Flu mRNA vaccine programs
